Literature DB >> 6505716

A phase I study of daunorubicin in advanced untreatable malignancies.

J Harvey, A Goodman, M McFadden, P Schein, F Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6505716

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  3 in total

1.  Phase I study of liposomal daunorubicin in patients with acute leukemia.

Authors:  J Cortes; S O'Brien; E Estey; F Giles; M Keating; H Kantarjian
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

3.  A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

Authors:  K J O'Byrne; A L Thomas; R A Sharma; M DeCatris; F Shields; S Beare; W P Steward
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.